$REVBAug 19, 2026, 9:00 AM ETAI processed
REVB hires Avance Clinical as CRO for Phase 2/3 TITAN AKI trial
AI Summary
Revelation Biosciences (REVB) has selected Avance Clinical as the CRO for its Phase 2/3 adaptive TITAN study testing Gemini in acute kidney injury and says the study is on track to start later this year. Avance touts global operations and a Renal Center of Excellence that could help recruitment and execution, but the company did not disclose enrollment targets, site count, primary endpoints, or any clinical data/timelines.
Positives
- Avance Clinical selected as CRO for Phase 2/3 TITAN study evaluating Gemini in AKI
- Company states study remains on track to begin later this year
- Avance has global operations and a Renal Center of Excellence that may aid patient recruitment and retention
Negatives
- No enrollment targets, site numbers, primary endpoints, or data timelines disclosed
- No clinical efficacy or safety data provided — trial is a future catalyst
- Study start and outcomes remain subject to typical clinical development and enrollment risks